Stage III Squamous Cell Carcinoma of the Lip and Oral Cavity Completed Phase 1 / 2 Trials for Erlotinib (DB00530)

IndicationStatusPhase
DBCOND0028768 (Stage III Squamous Cell Carcinoma of the Lip and Oral Cavity)Completed1 / 2
clinicaltrials.gov IdentifierTitlePurposeDrugs
NCT00055770Erlotinib Plus Docetaxel in Treating Patients With Locally Advanced, Metastatic, or Recurrent Head and Neck CancerTreatment
NCT00063895Erlotinib in Treating Patients With Advanced Non-Small Cell Lung Cancer, Ovarian Cancer, or Squamous Cell Carcinoma of the Head and NeckTreatment
NCT00101348Erlotinib and Cetuximab With or Without Bevacizumab in Treating Patients With Metastatic or Unresectable Kidney, Colorectal, Head and Neck, Pancreatic, or Non-Small Cell Lung CancerTreatment